10 powodów, dla których warto stosować naproksen w przypadku infekcji Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 1, 2024
Słowa kluczowe:
naproksen, mechanizm działania, terapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Naproksen to niesteroidowy lek przeciwzapalny, przeciwbólowy i przeciwgorączkowy, którego podstawowy mechanizm działania opiera się na hamowaniu syntezy prostaglandyn. Lek jest skuteczny w zwalczaniu bólu o zróżnicowanej etiologii, szczególnie w terapii reumatoidalnego zapalenia stawów. W odmiennym mechanizmie wywołuje bezpośrednie działanie przeciwwirusowe, wspiera także terapię zakażeń bakteryjnych, istotne znaczenie ma zdolność do depozycji w miejscu stanu zapalnego. W pracy omówiono szerokie możliwości terapeutyczne, które wyróżniają naproksen na tle innych niesteroidowych leków przeciwzapalnych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak, B. J. (2024). 10 powodów, dla których warto stosować naproksen w przypadku infekcji . Medycyna Faktów , 17(3(64), 384-390. https://doi.org/10.24292/01.MF.0324.11
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
2. Sękowska A. 10 powodów, dla których warto stosować naproksen w świetle nowych doniesień naukowych. Medycyna Faktów. 2021; 4(53): 400-7. https://doi.org/10.24292/01.MF.0421.8.
3. Zhang H, Wu Y, Lin Z et al. Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(22): e15840. http://doi.org/10.1097/MD.0000000000015840.
4. Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage. 1988; 3: 141-4.
5. Coskun O, Karakaş A, Savaşci U et al. The value of naproxen test as a diagnostic method to differentiate cause of fever. Taf Preventive Medicine Bulletin. 2012; 11: 779-82.
6. Unger M, Karanikas G, Kerschbaumer A et al. Fever of unknown origin (FUO) revised. Wien Klin Wochenschr. 2016; 128(21-22): 796-801.
7. Cetin II, Ekici F, Kocabas A et al. The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. Turk J Pediatr. 2016; 58(5): 473-9. http://doi.org/10.24953/turkjped.2016.05.003.390.
8. Cashman TM, Starns RJ, Johnson J et al. Comparative effects of naproxen and aspirin on fever in children. J Pediatr. 1979; 95(4): 626-9. http://doi.org/10.1016/s0022-3476(79)80784-2.
9. Paglia MDG, Silva MT, Lopes LC et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One. 2021; 16(4): e0248866. http://doi.org/10.1371/journal.pone.0248866.
10. Tarp S, Bartels EM, Bliddal H et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012; 64(11): 3511-21. http://doi.org/10.1002/art.34644. PMID: 22833186.
11. Ozdol C, Gulec S, Rahimov U et al. Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thromb Res. 2007; 119(4): 453-9. http://doi.org/10.1016/j.thromres.2006.11.003.
12. Woroń J, Wordliczek J. Farmakoterapia gorączki – jeżeli NLPZ to który, czyli dlaczego naproksen. Terapia. 2019; 12: 38-40.
13. Dilly S, Fotso A, Lejal N et al. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J Med Chem. 2018; 61: 7202-17.
14. Zheng W, Fan W, Zhang S et al. Naproxen exhibits broad anti-influenza virus activity in mice by impending viral nucleoprotein nuclear export. Cell Rep. 2019; 27: 1875-85.
15. Cao L, She Z, Zhao Y et al. Inhibition of RAN attenuates influenza a virus replication and nucleoprotein nuclear export. Emerg Microbes Infect. 2024; 13(1): 2387910. http://doi.org/10.1080/22221751.2024.2387910.
16. Robb CT, Goepp M, Rossi AG et al. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177(21): 4899-920. http://doi.org/10.1111/bph.15206.
17. Hung IFN, To KKW, Chan JFW et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest. 2017; 151: 1069-80.
18. Chiou WC, Hsu MS, Chen YT et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J Enzyme Inhib Med Chem. 2021; 36(1): 147-53.
19. Khodavirdipour A. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective. Glob Med Genet. 2021; 8(2): 78-81. http://doi.org/10.1055/s-0041-1726461.
20. Al-Horani RA, Kar S. Potential Anti-SARS-CoV-2 Therapeutics That Target the PostEntry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses. 2020; 12(10): 1092. http://doi.org/10.3390/v12101092.
21. bbKiani P, Scholey A, Dahl TA et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021; 13(4): 558. http://doi.org/10.3390/v13040558.
22. Asadi M, Sayar S, Radmanesh E et al. Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. Diabetes Metab Syndr. 2021; 15(6): 102319. http://doi.org/10.1016/j.dsx.2021.102319.
23. Terrier O, Dilly S, Pizzorno A et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021; 26(9): 2593. http://doi.org/10.3390/molecules26092593.
24. Castro VM, Ross RA, McBride SM et al. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. MedRxiv. 2020: 20061994.
25. Prozzi GR, Cañás M, Urtasun MA et al. Riesgo cardiovascular de los antiinflamatorios no esteroideos [Cardiovascular risk of non-steroidal anti-inflammatory drugs]. Medicina (B Aires). 2018; 78(5): 349-55.
26. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382: 769-79.
27. Woroń J. Miejsce naproksenu w farmakoterapii bólu i gorączki. Co wiemy w 2022 roku? Medycyna Faktów. 2022; 4(57): 401-3. https://doi.org/10.24292/01.MF.0422.4.
2. Sękowska A. 10 powodów, dla których warto stosować naproksen w świetle nowych doniesień naukowych. Medycyna Faktów. 2021; 4(53): 400-7. https://doi.org/10.24292/01.MF.0421.8.
3. Zhang H, Wu Y, Lin Z et al. Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(22): e15840. http://doi.org/10.1097/MD.0000000000015840.
4. Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage. 1988; 3: 141-4.
5. Coskun O, Karakaş A, Savaşci U et al. The value of naproxen test as a diagnostic method to differentiate cause of fever. Taf Preventive Medicine Bulletin. 2012; 11: 779-82.
6. Unger M, Karanikas G, Kerschbaumer A et al. Fever of unknown origin (FUO) revised. Wien Klin Wochenschr. 2016; 128(21-22): 796-801.
7. Cetin II, Ekici F, Kocabas A et al. The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. Turk J Pediatr. 2016; 58(5): 473-9. http://doi.org/10.24953/turkjped.2016.05.003.390.
8. Cashman TM, Starns RJ, Johnson J et al. Comparative effects of naproxen and aspirin on fever in children. J Pediatr. 1979; 95(4): 626-9. http://doi.org/10.1016/s0022-3476(79)80784-2.
9. Paglia MDG, Silva MT, Lopes LC et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One. 2021; 16(4): e0248866. http://doi.org/10.1371/journal.pone.0248866.
10. Tarp S, Bartels EM, Bliddal H et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012; 64(11): 3511-21. http://doi.org/10.1002/art.34644. PMID: 22833186.
11. Ozdol C, Gulec S, Rahimov U et al. Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thromb Res. 2007; 119(4): 453-9. http://doi.org/10.1016/j.thromres.2006.11.003.
12. Woroń J, Wordliczek J. Farmakoterapia gorączki – jeżeli NLPZ to który, czyli dlaczego naproksen. Terapia. 2019; 12: 38-40.
13. Dilly S, Fotso A, Lejal N et al. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J Med Chem. 2018; 61: 7202-17.
14. Zheng W, Fan W, Zhang S et al. Naproxen exhibits broad anti-influenza virus activity in mice by impending viral nucleoprotein nuclear export. Cell Rep. 2019; 27: 1875-85.
15. Cao L, She Z, Zhao Y et al. Inhibition of RAN attenuates influenza a virus replication and nucleoprotein nuclear export. Emerg Microbes Infect. 2024; 13(1): 2387910. http://doi.org/10.1080/22221751.2024.2387910.
16. Robb CT, Goepp M, Rossi AG et al. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177(21): 4899-920. http://doi.org/10.1111/bph.15206.
17. Hung IFN, To KKW, Chan JFW et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest. 2017; 151: 1069-80.
18. Chiou WC, Hsu MS, Chen YT et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J Enzyme Inhib Med Chem. 2021; 36(1): 147-53.
19. Khodavirdipour A. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective. Glob Med Genet. 2021; 8(2): 78-81. http://doi.org/10.1055/s-0041-1726461.
20. Al-Horani RA, Kar S. Potential Anti-SARS-CoV-2 Therapeutics That Target the PostEntry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses. 2020; 12(10): 1092. http://doi.org/10.3390/v12101092.
21. bbKiani P, Scholey A, Dahl TA et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021; 13(4): 558. http://doi.org/10.3390/v13040558.
22. Asadi M, Sayar S, Radmanesh E et al. Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. Diabetes Metab Syndr. 2021; 15(6): 102319. http://doi.org/10.1016/j.dsx.2021.102319.
23. Terrier O, Dilly S, Pizzorno A et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021; 26(9): 2593. http://doi.org/10.3390/molecules26092593.
24. Castro VM, Ross RA, McBride SM et al. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. MedRxiv. 2020: 20061994.
25. Prozzi GR, Cañás M, Urtasun MA et al. Riesgo cardiovascular de los antiinflamatorios no esteroideos [Cardiovascular risk of non-steroidal anti-inflammatory drugs]. Medicina (B Aires). 2018; 78(5): 349-55.
26. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382: 769-79.
27. Woroń J. Miejsce naproksenu w farmakoterapii bólu i gorączki. Co wiemy w 2022 roku? Medycyna Faktów. 2022; 4(57): 401-3. https://doi.org/10.24292/01.MF.0422.4.